Actuate Therapeutics receives Nasdaq notice over minimum bid price deficiency
ACTU•Actuate Therapeutics received a Nasdaq notice after its closing bid price stayed below $1 for 30 consecutive business days. It has until April 26, 2027, to meet the minimum bid-price requirement, while a separate notice sets January 11, 2027, as the deadline to meet minimum market value requirements.
1. Bid-price compliance deadline
Actuate Therapeutics received a Nasdaq notice on October 28, 2026, after its stock closed below the $1 minimum bid price for 30 consecutive business days. To regain compliance, it must maintain a closing bid price of at least $1 for 10 consecutive business days by April 26, 2027, while meeting other listing requirements.
2. Separate listing requirement
The notice has no immediate impact on the listing, and the company’s common stock continues trading on the Nasdaq Global Market under ACTU. A conditional 180-day extension may be available if the company transfers to the Nasdaq Capital Market; failure to regain compliance risks delisting. A separate notice issued July 15, 2026, set January 11, 2027, as the deadline to meet minimum market value of listed securities requirements.
